Pembrolizumab and Chemotherapy in High-Risk, Early-Stage, ER+/HER2− Breast Cancer: A Randomized Phase 3 Trial

Medicine, Oncology,
breast cancer   pembrolizumab   chemotherapy   randomized trial   pathological complete response  

Pembrolizumab Combined with Chemotherapy in High-Risk, Early-Stage ER+/HER2− Breast Cancer: A Randomized Phase 3 Trial Academic Background Breast cancer is one of the most common cancers among women worldwide, with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2−) breast cancer accounting for a significant pro...